CGPA

The federal budget tabled on November 4 includes important measures to support domestic life sciences and manufacturing investments. Budget 2025 did not provide the resources Health Canada urgently needs to address its growing backlog of generic and biosimilar drug submissions.…

The CGPA and its member companies would like to thank The Hon. @VictorFedeli Ontario’s Minister of Economic Development, Job Creation and Trade, along with The Hon. @ninatangri , and MPPs John Jordan, Frances Gélinas, and Lee Fairclough for meeting with us at Queen’s Park…

Time for Action: Investing in Health Canada to Accelerate Access to Affordable Medications, Jim Keon writes nationalnewswatch.com/2025/10/27/tim… @CdnGenerics

In a new op-ed for National Newswatch, Jim Keon, the president of CGPA and its Biosimilars Canada division, calls on the federal government to invest in Health Canada's drug review capacity to accelerate access to cost-saving generics and biosimilars. As Jim’s piece notes, right…

In British Columbia, a small shift could mean big savings. If BC increased its use of generic medicines by just 1%, the province could save more than $112 million per year on prescription drugs. Yes, you read that right: more than $100 million in savings with just a 1% increase…

The CGPA welcomes the decision by Quebec’s Ministry of Health and Social Services to increase the number of formulary updates to the lists of medications from 9 to 12 per year starting in 2026. This decision reflects Minister Christian Dubé’s clear commitment to accelerating…

Every small shift toward generic medicine adds up—and in Quebec's case, it adds up to a lot. Did you know that Quebec could save more than a quarter billion dollars by increasing its use of generic medicines by just 1%? It's true. A 1% increase in generics would save Quebec's…

If Canada's most populous province increased its use of generic pharmaceuticals by just 1%, the province could reduce their spending by almost half a billion dollars. Yes, half a billion. That’s such a large number that it's almost hard to believe, but it's true. If Ontario's…

When you pick up a generic prescription, you’re getting the exact same active ingredient, in the same amount, working the same way in your body as the brand-name drug. The only real difference? The price. The brand-name version of prescription medicines can cost up to 10 times…

Did you know that more than three-quarters of the medicines Canadians rely on every day are generic? More than 77% of prescriptions filled in Canada are generics, because they deliver the same quality, safety, and effectiveness as brand-name drugs at just a fraction of the cost…

The most boring conversation ever? Maybe not!!! Check out the second TV spot from our first-ever TV ad campaign. In this episode, "Generic" and "Brand Name" continue their argument about whether generic prescription medicines are as effective as their brand name counterparts.…

Improving the efficiency of Health Canada’s drug review process is a shared priority for federal Health Minister Marjorie Michel, the CGPA and its @CDNBiosimilars division. We look forward to working with Health Canada to cut red tape and speed up generic and biosimilar drug…

Health Canada’s generic review process is becoming increasingly unpredictable and unsustainable. As CGPA President Jim Keon recently told The Globe & Mail, “Health Canada acknowledges they’re picking up submissions late. They are short of resources. There’s a higher submission…

Are generic prescriptions just as effective as their brand name counterparts? If so, why do brand name drugs cost up to 10 times more? This month, CGPA introduces Canadians to two guys who debate generics vs brand name drugs. The CGPA is pleased to launch its first-ever TV ad…

Boosting the use of generic prescription medicines by a single percentage point could save Canada $1.234 billion. In the private sector, a one percent increase in generics would save more than $700 million, while a one percent increase in the public sector would save more than…

As concerns grow over U.S. President Donald Trump’s proposal to impose 200% tariffs on pharmaceutical imports, CGPA President Jim Keon has again shared his insights with the media, this time in a Canadian Press story published in the Financial Post. While the tariffs are not…

In response to U.S. President Donald Trump’s proposal of tariffs of up to 200% on pharmaceutical imports, CGPA President Jim Keon shared his perspective in today’s Toronto Star. While Canada represents just 5% of U.S. generic imports, Jim noted that the proposed tariffs would…

This Canada Day, we’re celebrating one of our country’s quiet strengths: our domestic generic pharmaceutical industry. Canada is one of the few nations in the world with robust, homegrown capacity to manufacture high-quality, safe, and cost-effective generic medicines. Our…

When it comes to filling prescriptions, generic pharmaceuticals punch way above their weight. In Canada, $48 billion is spent annually on prescription medicines. But even though generics are used to fill more than 78% of all prescriptions, they account for less than 23% of the…